Illumina Introduces BaseSpace® Informatics Suite to Accelerate Genomic Data Analysis for Sequence Labs

First Cloud-based, Sample-to-Answer Informatics Infrastructure to Enable Precision Medicine

SAN DIEGO–(BUSINESS WIRE)–Apr. 5, 2016– Illumina, Inc. (NASDAQ: ILMN) today introduced BaseSpace® Suite, the most complete suite of genomics software tools and solutions to facilitate precision medicine and genomics research. The integrated informatics solution enables users to engage with a unified, comprehensive platform from laboratory information management, analysis and sharing, to sample interpretation, reporting and advanced cohort analytics. BaseSpace Suite addresses critical issues in genomic data processing and analysis by reducing the time from sample submission to answer. It improves the overall accuracy of the results without the need to integrate point solutions from multiple vendors, allowing users to focus on the science.

BaseSpace Suite is ideal for use by a full range of labs, including clinical and translational labs, and research institutions, as well as any other entity that generates, analyzes and interprets genomic data.

“HudsonAlpha has found the capabilities of BaseSpace invaluable for our production lab,” said Howard Jacob, Chief Genomic Medical Officer and Vice President of Genomic Health at HudsonAlpha Institution for Biotechnology. “BaseSpace has been an outstanding complement to our in-house systems and tools.”

“Illumina is providing a comprehensive enterprise genomics platform that offers more capabilities than ever before,” said Sanjay Chikarmane, Senior Vice President and General Manager of Illumina’s Enterprise Informatics business unit. “As the global leader in next-generation sequencing, Illumina is uniquely positioned to deliver the most complete genomics informatics solution. Our expertise in genomics and deep knowledge of the needs of our customers have led us to build a more integrated bioinformatics ecosystem that is built to scale.”

BaseSpace Suite is built to be cloud-ready, providing a secure, scalable solution, simplifying data storage issues and providing a highly collaborative environment. The system provides pre-configured workflows and analysis pipelines to help users get started, and can be custom configured for use with individualized workflows and analysis pipelines. The platform is intuitive and user-friendly for a myriad of user types – from the clinical scientist to the lab director and researcher. For laboratories that would like implementation support, Illumina provides Professional Services for Bioinformatics to help set up and scale the software solution quickly in any sized lab.

Illumina is committed to providing the most complete sample-to-answer bioinformatics solutions for genomics in its enterprise informatics business with the recent acquisition of GenoLogics, a leading cloud-based genomics laboratory information management system provider in 2015, and the acquisition of NextBio in 2013.

BaseSpace Suite will be unveiled at Bio-IT World in Boston on April 5 at Booth 161. For more information, visit http://www.illumina.com/informatics.html.

About Illumina, Inc.

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.

Forward-Looking Statements

This release may contain forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160405005605/en/

Source: Illumina, Inc.

Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
ir@illumina.com
or
Media:
Mina Nicoletti
858-882-6822
pr@illumina.com